#88 Lenvatinib plus pembrolizumab versus chemotherapy as first-line therapy for advanced or recurrent endometrial cancer: primary results of the phase 3 ENGOT-en9/LEAP-001 study

Christian Marth, Richard G. Moore, Mariusz Bidziński, Sandro Pignata, Ali̇ Ayhan, María Jesús Rubio, Mario Beiner, Marcia Hall, Christof Vulsteke, Elena Ioana Braicu, Kenzo Sonoda, Xiaohua Wu, Sophia Frentzas, André Mattar, Jodi A. McKenzie, Lili Yao, Vivek Khemka, Lucy Gilbert, Vicky Makker